Zidovudine as an immunomodulatory agent

Area of Science:

• Immunology
• Pharmacology
• Reproductive Biology

Background:

• Rising HIV infection rates in women and transplacental transmission necessitate strategies to protect offspring.
• Zidovudine (AZT) is explored for preventing mother-to-child HIV transmission.
• Data on zidovudine's immunotoxicity in pregnant females and their progeny is limited.

Purpose of the Study:

• To evaluate zidovudine's immunotoxicity in pregnant mice (primiparous females) and their offspring.
• To establish a baseline understanding of zidovudine's effects on the immune system during pregnancy and early development.

Main Methods:

• Pregnant mice were exposed to zidovudine (0.2 mg/ml) in drinking water.
• Mixed lymphocyte response (MLR) and antibody-forming cell response were assessed in mothers and offspring.
• Different treatment regimens, including oral and intravenous administration, were tested.

Main Results:

• Zidovudine enhanced the MLR in pregnant mice initially, with suppression appearing later (7 months).
• Progeny exhibited profound and persistent MLR suppression starting at one week of age.
• Antibody-forming cell response was enhanced in mothers and offspring, but not virgin females.
• Treatment regimen influenced the timing and type of immune modulation observed.

Conclusions:

• Zidovudine demonstrates immunosuppressive effects on T-cell mediated immunity.
• The immunomodulatory impact of zidovudine is dependent on the specific treatment regimen.
• Findings highlight potential risks of zidovudine exposure during pregnancy and early development.